219 related articles for article (PubMed ID: 12724820)
1. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
Borges Lde G; Frõehlich PE
Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
[TBL] [Abstract][Full Text] [Related]
2. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
3. [New indications for thalidomide?].
Tuinmann G; Hegewisch-Becker S; Hossfeld DK
Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
[No Abstract] [Full Text] [Related]
4. The promise of thalidomide: evolving indications.
Joglekar S; Levin M
Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
7. Potential novel uses of thalidomide: focus on palliative care.
Peuckmann V; Fisch M; Bruera E
Drugs; 2000 Aug; 60(2):273-92. PubMed ID: 10983733
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic and nondermatologic uses of thalidomide.
Nasca MR; Micali G; Cheigh NH; West LE; West DP
Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for erythema nodosum leprosum and other applications.
Okafor MC
Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system.
Mathé G
Biomed Pharmacother; 2002 Feb; 56(1):1-3. PubMed ID: 11905504
[No Abstract] [Full Text] [Related]
11. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide: a review of approved and investigational uses.
Matthews SJ; McCoy C
Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
[TBL] [Abstract][Full Text] [Related]
13. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide: emerging role in cancer medicine.
Richardson P; Hideshima T; Anderson K
Annu Rev Med; 2002; 53():629-57. PubMed ID: 11818493
[TBL] [Abstract][Full Text] [Related]
15. Theoretical basis for the activity of thalidomide.
Meierhofer C; Dunzendorfer S; Wiedermann CJ
BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide. A new beginning.
Valorie AM
Cancer Pract; 2000; 8(2):101-3. PubMed ID: 11898173
[No Abstract] [Full Text] [Related]
17. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
18. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.
Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN
Biomed Pharmacother; 2002 Feb; 56(1):13-9. PubMed ID: 11905505
[TBL] [Abstract][Full Text] [Related]
19. Palliative oncology: thalidomide.
Prommer EE
Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide as a targeted therapy for multiple myeloma.
Dan K
Intern Med; 2003 Jul; 42(7):550-1. PubMed ID: 12879943
[No Abstract] [Full Text] [Related]
[Next] [New Search]